Christine Fox's most recent trade in Teva- Pharmaceutical Industries Ltd. - ADR was a trade of 17,819 Restricted Share Units done . Disclosure was reported to the exchange on March 5, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Teva- pharma Ind Ltd (ADR) | Christine Fox | EVP, U.S. Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2026 | 17,819 | 53,459 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Christine Fox | EVP, U.S. Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2026 | 17,819 | 92,829 (0%) | 0% | - | Ordinary Shares | |
| Teva- pharma Ind Ltd (ADR) | Christine Fox | EVP, U.S. Commercial | Sale of securities on an exchange or to another person at price $ 31.67 per share. | 05 Mar 2026 | 7,924 | 84,905 (0%) | 0% | 31.7 | 250,940 | Ordinary Shares |
| Teva- pharma Ind Ltd (ADR) | Christine Fox | EVP, U.S. Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2026 | 50,643 | 50,643 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Christine Fox | EVP, U.S. Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2026 | 20,461 | 84,108 (0%) | 0% | - | Ordinary Shares | |
| Teva- pharma Ind Ltd (ADR) | Christine Fox | EVP, U.S. Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2026 | 20,461 | 40,923 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Christine Fox | EVP, U.S. Commercial | Sale of securities on an exchange or to another person at price $ 32.46 per share. | 04 Mar 2026 | 9,098 | 75,010 (0%) | 0% | 32.5 | 295,362 | Ordinary Shares |
| Teva- pharma Ind Ltd (ADR) | Christine Fox | EVP, Head of U.S. Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2025 | 63,492 | 126,984 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Christine Fox | EVP, Head of U.S. Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2025 | 63,492 | 91,876 (0%) | 0% | - | Ordinary Shares | |
| Teva- pharma Ind Ltd (ADR) | Christine Fox | EVP, Head of U.S. Commercial | Sale of securities on an exchange or to another person at price $ 24.78 per share. | 20 Nov 2025 | 28,229 | 63,647 (0%) | 0% | 24.8 | 699,523 | Ordinary Shares |
| Teva- pharma Ind Ltd (ADR) | Christine Fox | EVP, Head of U.S. Commercial | Sale of securities on an exchange or to another person at price $ 25.11 per share. | 14 Nov 2025 | 30,000 | 28,384 (0%) | 0% | 25.1 | 753,321 | Ordinary Shares |
| Teva- pharma Ind Ltd (ADR) | Christine Fox | EVP, Head of U.S. Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 71,278 | 71,278 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Christine Fox | EVP, Head of U.S. Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 20,461 | 61,384 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Christine Fox | EVP, Head of U.S. Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 20,461 | 64,565 (0%) | 0% | - | Ordinary Shares | |
| Teva- pharma Ind Ltd (ADR) | Christine Fox | EVP, Head of U.S. Commercial | Sale of securities on an exchange or to another person at price $ 15.73 per share. | 04 Mar 2025 | 4,034 | 60,531 (0%) | 0% | 15.7 | 63,473 | Ordinary Shares |
| Teva- pharma Ind Ltd (ADR) | Christine Fox | EVP, Head of U.S. Commercial | Sale of securities on an exchange or to another person at price $ 15.91 per share. | 04 Mar 2025 | 2,147 | 58,384 (0%) | 0% | 15.9 | 34,166 | Ordinary Shares |
| Teva- pharma Ind Ltd (ADR) | Christine Fox | EVP, Head of U.S. Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2024 | 63,492 | 190,476 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Christine Fox | EVP, Head of U.S. Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2024 | 63,492 | 63,492 (0%) | 0% | - | Ordinary Shares | |
| Teva- pharma Ind Ltd (ADR) | Christine Fox | EVP, Head of U.S. Commercial | Sale of securities on an exchange or to another person at price $ 16.87 per share. | 20 Nov 2024 | 19,388 | 44,104 (0%) | 0% | 16.9 | 327,085 | Ordinary Shares |
| Teva- pharma Ind Ltd (ADR) | Christine Fox | EVP, Head of U.S. Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 81,845 | 81,845 | - | - | Restricted Share Units | |
| Mercury Systems Inc | Christine Fox Harbison | EVP and Chief Growth Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2023 | 12,032 | 52,220 (0%) | 0% | 0 | Common Stock | |
| Mercury Systems Inc | Christine Fox Harbison | EVP and Chief Growth Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2023 | 9,844 | 40,188 (0%) | 0% | 0 | Common Stock | |
| Mercury Systems Inc | Christine Fox Harbison | EVP and Chief Growth Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 15,172 | 15,172 (0%) | 0% | 0 | Common Stock | |
| Mercury Systems Inc | Christine Fox Harbison | EVP and Chief Growth Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 15,172 | 30,344 (0%) | 0% | 0 | Common Stock |